T3D2875

2917 T3D2875

Riluzole

Riluzole is only found in individuals that have used or taken this drug. It is a glutamate antagonist (receptors, glutamate) used as an anticonvulsant (anticonvulsants) and to prolong the survival of patients with amyotrophic lateral sclerosis. [PubChem]The mode of action of riluzole is unknown. Its pharmacological properties include the following, some of which may be related to its effect: 1) an inhibitory effect on glutamate release (activation of glutamate reuptake), 2) inactivation of voltage-dependent sodium channels, and 3) ability to interfere with intracellular events that follow transmitter binding at excitatory amino acid receptors. 1744-22-5

5070

C8H5F3N2OS

234.007470 White powder.

119°C

3.95e-02 g/L

Riluzole is well-absorbed (approximately 90%), with average absolute oral bioavailability of about 60% (CV=30%). A high fat meal decreases absorption, reducing AUC by about 20% and peak blood levels by about 45%.

The mode of action of riluzole is unknown. Its pharmacological properties include the following, some of which may be related to its effect: 1) an inhibitory effect on glutamate release (activation of glutamate reuptake), 2) inactivation of voltage-dependent sodium channels, and 3) ability to interfere with intracellular events that follow transmitter binding at excitatory amino acid receptors.

Riluzole is extensively metabolized to six major and a number of minor metabolites, which have not all been identified to date. Metabolism is mostly hepatic, consisting of cytochrome P450–dependent hydroxylation and glucuronidation. CYP1A2 is the primary isozyme involved in N-hydroxylation; CYP2D6, CYP2C19, CYP3A4, and CYP2E1 are considered unlikely to contribute significantly to riluzole metabolism in humans. Half Life: The mean elimination half-life of riluzole is 12 hours (CV=35%) after repeated doses. LD50: 85 mg/kg (p.o., mice) (L1859) LD50: 34.5 mg/kg (i.v, mice) (L1859) LD50: 45 mg/kg (p.o., rat) (L1859) LD50: 21 mg/kg (i.v, mice) (L1859) No indication of carcinogenicity to humans (not listed by IARC).

For the treatment of amyotrophic lateral sclerosis (ALS, Lou Gehrig's Disease)

May cause a potentially dangerous rash that may develop into Stevens Johnson syndrome, an extremely rare but potentially fatal skin disease.

Symptoms include such as nausea and fatigue [Wikipedia]. Treatment should be supportive and directed toward alleviating symptoms. Severe methemoglobinemia may be rapidly reversible after treatment with methylene blue. (L1712)

2009-07-21T20:27:32Z

2014-12-24T20:25:52Z

Riluzole

C07937

138898

Riluzole

DB00740

true

FC(F)(F)OC1=CC2=C(NC(=N)S2)C=C1

C8H5F3N2OS

InChI=1S/C8H5F3N2OS/c9-8(10,11)14-4-1-2-5-6(3-4)15-7(12)13-5/h1-3H,(H2,12,13)

InChIKey=FTALBRSUTCGOEG-UHFFFAOYSA-N

234.198

234.007468097

Exogenous Solid 2.3

HMDB14878

CHEMBL744

4892

Pratap Padi, Madhusudhan Ganta, Satyanarayana Bollikonda, Sridhar Chaganti, Ramulu Akula, Loka Maheshwari Dommati, “PROCESS FOR PREPARING RILUZOLE.” U.S. Patent US20080108827, issued May 08, 2008.